CAMK2G is identified as a novel therapeutic target for myelofibrosis

Masashi Miyauchi, Ken Sasaki, Yuki Kagoya, Kazuki Taoka, Yosuke Masamoto, Sho Yamazaki, Shunya Arai, Hideaki Mizuno, Mineo Kurokawa

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Although JAK1/2 inhibition is effective in alleviating symptoms of myelofibrosis (MF), it does not result in the eradication of MF clones, which can lead to inhibitor-resistant clones emerging during the treatment. Here, we established induced pluripotent stem cells (iPSCs) derived from MF patient samples (MF-iPSCs) harboring JAK2 V617F, CALR type 1, or CALR type 2 mutations. We demonstrated that these cells faithfully recapitulate the drug sensitivity of the disease. These cells were used for chemical screening, and calcium/ calmodulin-dependent protein kinase 2 (CAMK2) was identified as a promising therapeutic target. MF model cells and mice induced by MPL W515L, another type of mutation recurrently detected in MF patients, were used to elucidate the therapeutic potential of CAMK2 inhibition. CAMK2 inhibition was effective against JAK2 inhibitor-sensitive and JAK2 inhibitor-resistant cells. Further research revealed CAMK2 g subtype was important in MF model cells induced by MPL W515L. We showed that CAMK2G hetero knockout in the primary bone marrow cells expressing MPL W515L decreased colony-forming capacity. CAMK2G inhibition with berbamine, a CAMK2G inhibitor, significantly prolonged survival and reduced disease phenotypes, such as splenomegaly and leukocytosis in a MF mouse model induced by MPL W515L. We investigated the molecular mechanisms underlying the therapeutic effect of CAMK2G inhibition and found that CAMK2G is activated by MPL signaling in MF model cells and is an effector in the MPL-JAK2 signaling pathway in these cells. These results indicate CAMK2G plays an important role in MF, and CAMK2G inhibition may be a novel therapeutic strategy that overcomes resistance to JAK1/2 inhibition.

Original languageEnglish
Pages (from-to)1585-1597
Number of pages13
JournalBlood Advances
Issue number5
Publication statusPublished - 2022 Mar 8
Externally publishedYes

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'CAMK2G is identified as a novel therapeutic target for myelofibrosis'. Together they form a unique fingerprint.

Cite this